title: A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant.
abstract: Two determinants of infectivity have been identified in the hepatitis B virus (HBV) envelope proteins: a pre-S1 receptor-binding site and an uncharacterized determinant in the antigenic loop (AGL), which is structurally related to the antigenic a-determinant. Infection would proceed through virus attachment to cell surface heparan sulfate (HS) proteoglycans (HSPGs) before pre-S1 engages a specific receptor for uptake. Using heparin binding and in vitro infection assays with hepatitis D virus as a surrogate for HBV, we established that HS binding is mediated by the AGL. Electrostatic interaction was shown to depend upon AGL residues R122 and K141, because their substitution with alanine modified the virus net-charge and prevented binding to heparin, attachment to hepatocytes, and infection. In addition to R122 and K141, the HS binding determinant was mapped to cysteines and prolines, which also define the conformational a-determinant. The importance of AGL conformation was further demonstrated by the concomitant loss of a-determinant and heparin binding upon treatment of viral particles with membrane-impermeable reducing agent. Furthermore, envelope proteins extracted from the viral membrane with a nonionic detergent were shown to conserve the a-determinant but to lose heparin affinity/avidity.
  
  
  CONCLUSIONS
  Our findings support a model in which attachment of HBV to HSPGs is mediated by the AGL HS binding site, including only two positively charged residues (R122 and K141) positioned precisely in a three-dimensional AGL structure that is stabilized by disulfide bonds. HBV envelope proteins would individually bind to HS with low affinity, but upon their clustering in the viral membrane, they would reach sufficient avidity for a stable interaction between virus and cell surface HSPGs. Our data provide new insight into the HBV entry pathway, including the opportunity to design antivirals directed to the AGL-HS interaction.
authors.affiliation: Laboratoire de Virologie Moléculaire, INTS, Centre National de la Recherche Scientifique, Paris, France. csureau@ints.fr
authors.forename: Camille
authors.initials: C
authors.lastname: Sureau
authors.forename: Jessica
authors.initials: J
authors.lastname: Salisse
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives / Q000378:metabolism; D019943:Amino Acid Substitution; D001665:Binding Sites / Q000187:drug effects / Q000502:physiology; D003902:Detergents / Q000494:pharmacology; D006497:Heparan Sulfate / Q000737:chemistry / Q000378:metabolism*; D006509:Hepatitis B / Q000821:virology*; D006514:Hepatitis B Surface Antigens / Q000737:chemistry / Q000378:metabolism*; D006515:Hepatitis B virus / Q000254:growth & development / Q000378:metabolism*; D006801:Humans; D055767:Immobilized Proteins / Q000737:chemistry / Q000378:metabolism; D017434:Protein Structure, Tertiary / Q000502:physiology; D014357:Trypsin / Q000494:pharmacology; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000378:metabolism; D014771:Virion / Q000378:metabolism*
chemical_list: D000409:Alanine; D003902:Detergents; D006497:Heparan Sulfate; D006514:Hepatitis B Surface Antigens; D055767:Immobilized Proteins; D014357:Trypsin; D014759:Viral Envelope Proteins; C046025:alaninal